Advanced Practice Providers (APPs) represent the future of TRT, often practicing at the top of their license. These Nurse Practitioners and Physician Assistants are increasingly responsible for the diagnosis, initial treatment, dosing, titration, and ongoing management of TRT.
Based on insights from APPs actively managing TRT, this page was developed to address the real-world challenges they encounter in everyday practice. The resources provide practical guidance and peer-informed strategies to support clinicians across the full TRT care continuum, from patient evaluation and therapy initiation to monitoring and long-term management.
Join experienced APPs as they explore practical, real-world strategies for TRT management in a peer-to-peer video series. Watch each full video on the So They’re on TRT… Now What? YouTube Channel
APPs trust and value peer-led education:
consider educational content presented by an APP as equally or more valuable than content from a physician.1
believe APPs have the same level of expertise as physicians on general health topics.1
are more or as likely to attend an on-demand educational event presented by an APP versus a physician.1
find APP-presented content more relevant to their day-to-day practice.1
Insights drawn from physician peer discussions, supported by Tolmar sponsored State-of-TRT studies, highlighting common considerations in the management of patients receiving testosterone replacement therapy, including:
Down from 90% in 2024
Flat from 2024
Up from 42% in 2024
Up from 50% in 2024
42% (across both years) cite toxicity liver concerns as the major barrier
Dive into peer-driven discussions that address real-world TRT management challenges. Learn practical strategies, see how other experienced APPs approach therapy adjustments, and explore actionable insights by visiting our YouTube channel.
JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:
Safety and efficacy of JATENZO in men with “age-related hypogonadism” and in males less than 18 years old have not been established.
JATENZO is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate, in women who are pregnant, or in men with a known hypersensitivity to JATENZO or its ingredients.
Increase in hematocrit and polycythemia. High red blood cell counts increase the risk of clots, strokes, and heart attacks.
Venous thromboembolic events (VTE). Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone replacement products like JATENZO.
Benign prostatic hyperplasia (BPH). Patients may see worsening signs and symptoms of BPH.
Prostate cancer. Patients treated with androgens may be at increased risk for prostate cancer.
Blood pressure increases. JATENZO can increase blood pressure. Monitor blood pressure periodically in men using JATENZO. Not recommended for use with uncontrolled hypertension.
Abuse. Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Testosterone abuse can lead to serious cardiovascular and psychiatric adverse reactions.
Suppression of spermatogenesis. Large doses of androgens, like JATENZO, can suppress spermatogenesis.
Hepatic adverse events. JATENZO is not known to cause liver adverse events; however, patients should be instructed to report any signs of hepatic dysfunction.
Retention of sodium and water.
Gynecomastia.
Sleep apnea. Testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.
Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy.
Risk of hypercalcemia.
The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).
JATENZO can cause changes in insulin sensitivity or glycemic control and changes in anticoagulant activity. Use of testosterone and corticosteroids concurrently may increase fluid retention. Use of prescription and nonprescription analgesic cold medications with JATENZO have been known to increase blood pressure.
To report suspected adverse reactions contact Tolmar at 1-844-4TOLMAR (486-5627) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Please see full Prescribing Information.
References
1. Data on file. Sermo RealTime Study: Understanding educational preferences of APPs (conducted online during January 2025). Tolmar, Inc.
2. Data on file. The 2nd Annual Landmark SERMO survey: The state of TRT in 2025. (conducted August 1-September 15, 2025).
